In Wednesday’s Wall Street session, Roivant Sciences Ltd (NASDAQ:ROIV) shares traded at $11.21, down -0.31% from the previous session.
ROIV stock price is now 5.49% away from the 50-day moving average and -0.50% away from the 200-day moving average. The market capitalization of the company currently stands at $7.62B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 566,278 shares of the company’s stock on Jun 03 ’25. The stock was sold for $6,353,639 at an average price of $11.22. Upon completion of the transaction, the President & COO now directly owns 1,462,223 shares in the company, valued at $16.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02 ’25, President & COO Venker Eric sold 433,722 shares of the business’s stock. A total of $4,801,303 was realized by selling the stock at an average price of $11.07. This leaves the insider owning 1,243,475 shares of the company worth $13.94 million. A total of 38.56% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $8.73 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 33.47, and a quick ratio of 33.47. The fifty day moving average price for ROIV is $10.6265 and a two-hundred day moving average price translates $11.266125 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for 2025-03-31. The net profit margin was -225.71% and return on equity was -8.56% for ROIV.
